A biotechnology company based in Eastern Poland can boast a long history in promoting health and saving people's life. It specialises in implementing innovative technologies and building alliances with universities, research. The company constantly develops innovative products and product indications, conducts clinical trials, improves quality, safety and technology. It expands production capacity to respond to growing demand. It specializes not only in immunotherapy using BCG (Bacillus Calmette-Guérin) but also has the know-how and infrastructure for the production of blood-derived drugs i.e. human anti-D immunoglobulin for prevention Rh isoimmunization in Rh(D)- negative women. Medicine used in treatment of superficial non-invasive tumours of the urinary bladder is live, attenuated BCG bacilli, the Brazilian Moreau substrain in two doses 50 and 100 mg.
The company is also manufacturing an original topically applied enzyme combination effective in improving anti-inflammatory treatment, relieving pelvic pain and accelerating perioperative outcomes, using two enzymes Streptokinase and Streptodornase.
The company offers drugs for the treatment of bladder cancer, BCG anti-tuberculosis vaccine and proteolytic enzymes. Currently, the company is interested in expanding new markets that is why it is searching for distributors and agents for its immunotherapeutic drugs.
Advantages & innovations
The only Polish manufacturer of BCG tuberculosis vaccine for over 70 years and one of the few in Europe.
Many years of foreign cooperation, distribution of drugs in countries such as Germany, Turkey, Ukraine and others.
Investing in modern production lines and R&D center.
The company holds GMP (Good Manufacturing Practices) certificate.
Stage of development
POLAND
Partner sought
The company is interested in cooperation under distribution and commercial agency agreement. The foreign partners should have established network of contacts from biotechnological sector and experience in foreign collaboration.